Search
Potassium alum
go.drugbank.com/drugs/DB09087ApprovedWithdrawnPotassium alum is considered by the FDA as a generally recognized as safe (GRAS) substance. … Potassium alum is formed by large, transparent crystals that are used in different products like food or drugs as a buffer, neutralizing or forming agent.[T60]
Erenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalIn particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity binding to the CGRP receptor [FDA Label]. … Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the
Lomitapide
go.drugbank.com/drugs/DB08827Approvedextremely high levels of low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]
Disulfiram
go.drugbank.com/drugs/DB00822ApprovedInvestigationalIt is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. … It acts by inhibiting aldehyde dehydrogenase.
Influenza A virus A/Michigan/45/2015 X-275 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14458ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Mixtures: FLUZONE High-Dose, FLUZONE High-DoseMecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalMecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].
Influenza A virus A/Darwin/9/2021 SAN-010 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16916ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Mixtures: Fluzone High Dose Northern Hemisphere, FLUZONE High-Dose Quadrivalent Northern HemisphereFlortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigationalIt was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114] … Although flortaucipir F-18 displays low levels of background binding throughout the brain,[A203936] it does display off-target binding to monoamine oxidase MAO-A and MAO-B, as well as to regions containing high
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigational[L50773] The drug was also approved by the EMA on September 23, 2024.[L51878] … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).
Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell